Sunday 18 October 2026 Export ABEO’s income statement to Excel — free account

Abeona Therapeutics Inc.

Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

4.43 0.22 −4.73%

Follow ABEO

Alert me

Market cap: $265.9M
P/E: 0.0×
Fwd P/E: −7.4×
Dividend yield: —
F-score: n/a
Altman Z: −2.32
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.57

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	5	5	2	—	3	6	5	—	5	—

Insider Ownership 11.13%

Capital & Financial Ratios $m

Market Cap 265.90

Revenue 25.92

Net Income (62.89)

Free Cash Flow (81.53)

Net Debt (131.84)

Current Ratio 6.63

Debt/Equity 0.12

P/E ratio 0.00

Fwd P/E (7.39)

P/S ratio 9.68

P/B ratio 1.96

Past 5Y EPS Growth —

This Y EPS Growth (195.79%)

Next Y EPS Growth 80.95%

Next Y revenue growth 916.06%

Next 5Y EPS Growth (27.34%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.56%

10-year low 10-year high

P/B against its own 10 years 45.21%

10-year low 10-year high

EV/Sales against its own 10 years 13.63%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	53	98	191	147
Receivables	2	2	7	10
Inventory	—	—	5	6
Other	—	—	—	—
	56	101	205	165

	2023	2024	2025	Q'26
Payables	2	3	8	3
ST’ Debt	—	6	12	13
Other	0	0	0	—
	13	17	30	25

Compound Annual Growth %

	10y	5y	3y
Sales	(2.27%)	14.19%	24.72%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	8.92%	9.20%	81.20%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	11	—	—	—
’25	—	0	—	5	6
’23	—	4	—	—	4
’22	0	1	—	0	1
’21	—	—	—	3	3
’20	—	—	7	3	10
’18	1	0	2	0	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(17)	—	—	—
’25	(18)	(19)	(21)	(18)	(76)
’24	(15)	(13)	(12)	(17)	(56)
’23	(12)	(10)	(6)	(9)	(37)
’22	(14)	(9)	(7)	(14)	(43)
’21	(14)	(11)	(10)	(30)	(66)
’20	(13)	(9)	(11)	(2)	(35)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(18)	—	—	—
’25	(20)	(22)	(24)	(19)	(84)
’24	(15)	(13)	(13)	(17)	(58)
’23	(12)	(10)	(6)	(9)	(37)
’22	(14)	(8)	(7)	(14)	(42)
’21	(14)	(12)	(11)	(34)	(70)
’20	(14)	(10)	(11)	(2)	(36)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	(0.35)	—	—	—
’25	(0.24)	1.71	(0.10)	(0.34)	1.01
’24	(1.16)	0.14	(0.63)	(0.14)	(1.55)
’23	(0.54)	(0.92)	(0.48)	(0.64)	(2.53)
’22	(3.50)	(2.08)	(1.00)	0.46	(5.53)
’21	(4.25)	(4.00)	(1.75)	(11.25)	(21.50)
’20	(13.00)	(3.50)	(2.00)	(4.25)	(22.75)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	51.25	112.50	156.50	36.50	24.75	6.75	2.34	2.19	3.05	3.93	Analyst estimates 2026–2028 Powerpack
	High	236.00	568.75	550.00	210.25	108.50	94.75	9.75	5.40	9.01	7.54
People
People	Employees	19	42	83	88	76	90	57	84	136	226
	Revenue/emp, $m	0.05	0.02	0.04	0.00	0.13	0.03	0.02	0.04	0.00	0.03
Income, $m
Income, $m	Revenue	1	1	3	—	10	3	1	4	—	6
	Gross margin, %	100.00	100.00	100.00	0.00	100.00	100.00	68.18	54.14	—	73.68
	EBT	(22)	(27)	(57)	(76)	(84)	(85)	(40)	(54)	(64)	71
	EBT margin, %	(2,460.40)	(3,263.92)	(1,890.29)	0.00	(842.34)	(2,831.20)	(2,807.36)	(1,548.23)	0.00	1,224.79
	Net income	(22)	(27)	(57)	(76)	(84)	(85)	(40)	(54)	(64)	71
	Depreciation	1	1	2	8	6	4	5	3	3	4
Per share, $
Per share, $	Revenue	0.65	0.50	1.58	0.00	2.70	0.76	0.18	0.16	0.00	0.11
	Earnings	(16.00)	(16.50)	(29.75)	(37.75)	(22.75)	(21.50)	(5.53)	(2.53)	(1.55)	1.34
	Cash flow	(9.52)	(13.60)	(20.57)	(31.19)	(9.45)	(16.67)	(5.53)	(1.73)	(1.36)	(1.44)
	Capex	(0.38)	(0.52)	(4.86)	(3.13)	(0.36)	(1.05)	0.20	(0.01)	(0.06)	(0.15)
	Free cash flow	(9.90)	(14.12)	(25.43)	(34.32)	(9.81)	(17.73)	(5.33)	(1.74)	(1.42)	(1.59)
	Book value	72.48	102.13	70.51	88.59	27.67	10.76	3.40	0.69	1.07	3.01
	Shares, m	1	2	2	2	4	4	8	21	41	53
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00	—	4.02
	P/S	192.24	855.63	113.19	—	11.93	2.48	5.09	24.06	—	29.73
	P/B	1.72	4.21	2.53	—	1.42	0.79	0.84	7.97	—	1.75
	EV/Sales	118.96	695.84	86.18	—	4.42	(0.60)	(5.07)	14.52	—	11.47
	EV/FCF	(7.81)	(24.77)	(5.34)	—	(1.48)	0.12	0.53	(1.92)	—	(1.28)
Cash, $m
Cash, $m	Operating cash flow	(13)	(23)	(39)	(63)	(35)	(66)	(43)	(37)	(56)	(76)
	Capex	(1)	(1)	(9)	(6)	(1)	(4)	2	0	(2)	(8)
	Free cash flow	(14)	(24)	(48)	(69)	(36)	(70)	(42)	(37)	(58)	(84)
Balance, $m
Balance, $m	Working capital	61	135	68	94	56	40	45	42	84	175
	Total debt	—	—	—	8	3	9	8	—	19	20
	Net debt	(69)	(138)	(85)	(121)	(92)	(42)	(45)	(53)	(79)	(171)
	Shareholders’ equity	99	170	134	178	103	42	27	15	44	159
Returns, %
Returns, %	ROA	(22.89)	(18.85)	(32.09)	(38.35)	(44.98)	(73.61)	(60.47)	(84.53)	(73.71)	43.34
	ROIC	(49.83)	(53.78)	(74.07)	(84.35)	(463.12)	(6,756.62)	0.00	0.00	0.00	0.00
	ROE	(26.22)	(20.30)	(37.27)	(48.82)	(59.96)	(117.22)	(125.79)	(260.60)	(216.57)	70.05

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NAUT Nautilus Biotechnology, Inc.	$274.9M	— (loss-making)	—	—	n/m	−3.16% (below 0%: shrinking)	92.11%	(8,296.32%)	Compare
IPSC Century Therapeutics, Inc.	$271.6M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$266.7M	—	—	+346.33%	—	+7.09%	96.06%	(228.53%)

All 614 Biotechnology stocks →

Abeona Therapeutics Inc. (ABEO) key facts

Strength: Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023.
Abeona Therapeutics Inc. (ABEO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ABEO traded at $4.43, a market capitalization of $265.9 million.
Return on equity was 70.1% and debt-to-equity 0.12.
Its Altman Z-score is −2.32 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.